MX2022010874A - Lactoferrina de uso oral con accion antiviral. - Google Patents
Lactoferrina de uso oral con accion antiviral.Info
- Publication number
- MX2022010874A MX2022010874A MX2022010874A MX2022010874A MX2022010874A MX 2022010874 A MX2022010874 A MX 2022010874A MX 2022010874 A MX2022010874 A MX 2022010874A MX 2022010874 A MX2022010874 A MX 2022010874A MX 2022010874 A MX2022010874 A MX 2022010874A
- Authority
- MX
- Mexico
- Prior art keywords
- lactoferrin
- oral use
- antiviral action
- viral infections
- antiviral
- Prior art date
Links
- 102000010445 Lactoferrin Human genes 0.000 title abstract 2
- 108010063045 Lactoferrin Proteins 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title abstract 2
- 229940078795 lactoferrin Drugs 0.000 title abstract 2
- 235000021242 lactoferrin Nutrition 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 3
- 230000009385 viral infection Effects 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000315672 SARS coronavirus Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición que comprende lactoferrina para su uso por vía oral como antiviral, preferentemente para su uso en el tratamiento de infecciones virales del sistema respiratorio y de los síntomas o los trastornos derivados de dichas infecciones virales, o relacionados con ellas, preferentemente infecciones virales por coronavirus SARS (por ejemplo, COVID-19).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000005011A IT202000005011A1 (it) | 2020-03-09 | 2020-03-09 | Lattoferrina per uso orale ad azione antivirale |
| PCT/IB2020/059695 WO2020250209A2 (en) | 2020-03-09 | 2020-10-15 | Lactoferrin for oral use with antiviral action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010874A true MX2022010874A (es) | 2022-10-07 |
Family
ID=70804945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010874A MX2022010874A (es) | 2020-03-09 | 2020-10-15 | Lactoferrina de uso oral con accion antiviral. |
| MX2022010870A MX2022010870A (es) | 2020-03-09 | 2021-03-09 | Composicion que comprende lactoferrina y cepas bacterianas probioticas para uso oral con accion antiviral. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010870A MX2022010870A (es) | 2020-03-09 | 2021-03-09 | Composicion que comprende lactoferrina y cepas bacterianas probioticas para uso oral con accion antiviral. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230080695A1 (es) |
| EP (2) | EP4117711A2 (es) |
| JP (2) | JP2023516461A (es) |
| CN (2) | CN115697382A (es) |
| AU (2) | AU2020292850A1 (es) |
| BR (2) | BR112022017243A2 (es) |
| CA (2) | CA3174706A1 (es) |
| IL (2) | IL295528A (es) |
| IT (1) | IT202000005011A1 (es) |
| MX (2) | MX2022010874A (es) |
| WO (2) | WO2020250209A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2593452A (en) * | 2020-03-16 | 2021-09-29 | Mead Johnson Nutrition Co | Use of lactoferrin |
| WO2021222584A2 (en) * | 2020-04-29 | 2021-11-04 | The Regents Of The University Of Michigan | Inhibition of sars-cov-2 viral entry through administration of lactoferrin and uses thereof |
| IT202000009430A1 (it) * | 2020-04-29 | 2021-10-29 | Tdc Tech Dedicated To Care Srl | Composizione per la prevenzione e/o il trattamento delle infezioni delle vie respiratorie |
| WO2022162254A1 (es) * | 2021-02-01 | 2022-08-04 | Dermopartners,S.L. | Composición para su uso en forma de gotas nasales y nebulizadores como antiviral |
| WO2022172523A1 (ja) * | 2021-02-09 | 2022-08-18 | 森永乳業株式会社 | プラズマサイトイド樹状細胞活性化用組成物 |
| WO2024018374A1 (en) | 2022-07-20 | 2024-01-25 | Frimline Private Limited | A pharmaceutical composition providing mucolytic effect |
| CN116509821A (zh) * | 2023-03-07 | 2023-08-01 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂在制备用于冠状病毒引起感染性疾病治疗药物中的用途 |
| CN117018169A (zh) * | 2023-10-07 | 2023-11-10 | 广州菲勒生物科技有限公司 | 一种预防呼吸道病毒感染的营养组合物制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4486501A (en) * | 2000-03-27 | 2001-10-08 | Pharming Intellectual Property Bv | High dosage parenteral administration of lactoferrin |
| WO2006047744A2 (en) * | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| WO2009100331A2 (en) * | 2008-02-06 | 2009-08-13 | The Procter & Gamble Company | Compositions methods and kits for enhancing immune response to a respiratory condition |
| IT1392672B1 (it) * | 2009-01-12 | 2012-03-16 | Wyeth Consumer Healthcare S P A | Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina |
| KR101235561B1 (ko) * | 2010-12-09 | 2013-03-21 | 주식회사 제일바이오 | 항바이러스 및 항균 활성을 갖는 락토바실러스 플란타룸 ｃｌｐ-1 균주 및 이를 포함하는 생균제 |
| US20170246262A1 (en) * | 2016-02-25 | 2017-08-31 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| WO2019089878A1 (en) * | 2017-11-02 | 2019-05-09 | Colorado Seminary, Owner and Operator of University of Denver | Methods of treating microbial infection and inflammation |
-
2020
- 2020-03-09 IT IT102020000005011A patent/IT202000005011A1/it unknown
- 2020-10-15 WO PCT/IB2020/059695 patent/WO2020250209A2/en unknown
- 2020-10-15 MX MX2022010874A patent/MX2022010874A/es unknown
- 2020-10-15 AU AU2020292850A patent/AU2020292850A1/en active Pending
- 2020-10-15 IL IL295528A patent/IL295528A/en unknown
- 2020-10-15 CN CN202080098096.3A patent/CN115697382A/zh not_active Withdrawn
- 2020-10-15 BR BR112022017243A patent/BR112022017243A2/pt unknown
- 2020-10-15 US US17/798,050 patent/US20230080695A1/en active Pending
- 2020-10-15 CA CA3174706A patent/CA3174706A1/en active Pending
- 2020-10-15 EP EP20796654.0A patent/EP4117711A2/en active Pending
- 2020-10-15 JP JP2022554336A patent/JP2023516461A/ja active Pending
-
2021
- 2021-03-09 EP EP21716547.1A patent/EP4117710A1/en active Pending
- 2021-03-09 AU AU2021235546A patent/AU2021235546A1/en active Pending
- 2021-03-09 MX MX2022010870A patent/MX2022010870A/es unknown
- 2021-03-09 BR BR112022017308A patent/BR112022017308A2/pt unknown
- 2021-03-09 IL IL295525A patent/IL295525A/en unknown
- 2021-03-09 WO PCT/IB2021/051959 patent/WO2021181276A1/en unknown
- 2021-03-09 CN CN202180019922.5A patent/CN115279397A/zh not_active Withdrawn
- 2021-03-09 CA CA3174733A patent/CA3174733A1/en active Pending
- 2021-03-09 US US17/798,052 patent/US20230330164A1/en active Pending
- 2021-03-09 JP JP2022554327A patent/JP2023517327A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023516461A (ja) | 2023-04-19 |
| IL295525A (en) | 2022-10-01 |
| BR112022017243A2 (pt) | 2022-10-18 |
| MX2022010870A (es) | 2023-01-04 |
| IL295528A (en) | 2022-10-01 |
| CA3174706A1 (en) | 2020-12-17 |
| EP4117710A1 (en) | 2023-01-18 |
| CN115697382A (zh) | 2023-02-03 |
| WO2021181276A1 (en) | 2021-09-16 |
| EP4117711A2 (en) | 2023-01-18 |
| US20230080695A1 (en) | 2023-03-16 |
| AU2021235546A1 (en) | 2022-09-08 |
| CN115279397A (zh) | 2022-11-01 |
| WO2020250209A3 (en) | 2021-02-18 |
| IT202000005011A1 (it) | 2021-09-09 |
| BR112022017308A2 (pt) | 2022-10-11 |
| JP2023517327A (ja) | 2023-04-25 |
| CA3174733A1 (en) | 2021-09-16 |
| AU2020292850A1 (en) | 2022-09-08 |
| US20230330164A1 (en) | 2023-10-19 |
| WO2020250209A2 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010874A (es) | Lactoferrina de uso oral con accion antiviral. | |
| CR20220675A (es) | Análogos de nucleósido de 1´- ciano y usos de los mismos | |
| PH12020550531A1 (en) | Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv) | |
| SG163517A1 (en) | Antiviral compounds and methods | |
| TW200510343A (en) | Substituted dihydroquinazolines | |
| PH12017501958A1 (en) | Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds | |
| MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
| NO20091441L (no) | Rekonstituerte surfaktanter med forbedrede egenskaper | |
| MX2022010877A (es) | Cepas bacterianas y composiciones de las mismas para uso oral en el tratamiento de infecciones virales del aparato respiratorio. | |
| PH12019550039A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| ZA202209180B (en) | Compositions and methods for treating long covid | |
| MX2022016066A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| HK1097467A1 (en) | Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids | |
| MX2021004860A (es) | Piridazinas novedosas. | |
| MX2020010738A (es) | Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos). | |
| MX2023002667A (es) | Compuestos y metodos para el tratamiento de infecciones virales. | |
| MX2022013195A (es) | Uso de proteina surfactante d para tratar infecciones virales. | |
| MX2022013814A (es) | Tratamiento de infecciones virales. | |
| MX2022012576A (es) | Inhibidores de axl para terapia antiviral. | |
| DK1511466T3 (da) | Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD | |
| MX2022011475A (es) | Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus. | |
| MX2021002936A (es) | Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada. | |
| MX2023008885A (es) | Metodos para prevenir infeccion viral. | |
| MX2023005302A (es) | Uso de arnm de ifn-lambda para el tratamiento de infecciones viricas. |